$XERI
XERIANT, INC. Stock $xeri

$xeri Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000147793223007646 Filed on October 16, 2023

Income Statement

Concept	2023 Q4	2023 Q2	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$184.5K	-$710.0K	$326.0K
YoY Change	-46.11%	-151.85%	-93.3%
% of Gross Profit
Research & Development	$52.75K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
% of Gross Profit
Depreciation & Amortization	$760.00	$0.00	$0.00
YoY Change	105.41%	-100.0%	-100.0%
% of Gross Profit
Operating Expenses	$339.9K	$390.0K	$2.052M
YoY Change	-36.93%	-72.71%	-81.37%
Operating Profit	-$339.9K		-$2.052M
YoY Change	-36.93%		-81.37%
Interest Expense	$846.7K	-$50.00K	$10.57K
YoY Change		-97.01%	-92.4%
% of Operating Profit
Other Income/Expense, Net	-$867.0K		-$5.045M
YoY Change	14.78%		-203.59%
Pretax Income	-$1.207M	-$600.0K	-$7.100M
YoY Change	-6.76%	-80.66%	-55.3%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$1.207M	-$590.0K	-$7.067M
YoY Change	-6.76%	-84.24%	-55.5%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	$0.00	$0.00	-$0.02
COMMON SHARES
Basic Shares Outstanding	401.0M shares	381.9M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2023 Q2	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$38.98K	$60.00K	$60.00K
YoY Change	-82.87%	-94.66%	-94.66%
Cash & Equivalents	$38.98K	$61.63K
Short-Term Investments
Other Short-Term Assets	$6.280K	$0.00	$0.00
YoY Change	-72.78%	-100.0%	-100.0%
Inventory
Prepaid Expenses	$6.284K	$4.529K
Receivables	$8.160K
Other Receivables	$0.00
Total Short-Term Assets	$53.43K	$66.15K	$70.00K
YoY Change	-78.68%	-94.18%	-93.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.751K	$5.507K	$90.00K
YoY Change	-24.14%	24.9%	-32.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Assets	$12.55K	$10.00K	$10.00K
YoY Change		0.0%	0.0%
Total Long-Term Assets	$75.58K	$101.0K	$100.0K
YoY Change	-32.82%	-23.94%	-24.67%
TOTAL ASSETS
Total Short-Term Assets	$53.43K	$66.15K	$70.00K
Total Long-Term Assets	$75.58K	$101.0K	$100.0K
Total Assets	$129.0K	$167.1K	$170.0K
YoY Change	-64.47%	-86.84%	-86.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.089M	$400.0K	$400.0K
YoY Change	589.42%	603.73%	603.73%
Accrued Expenses	$67.31K	$80.00K	$80.00K
YoY Change	-41.29%	12.74%	12.74%
Deferred Revenue
YoY Change
Short-Term Debt	$5.850M	$6.200M	$6.200M
YoY Change	0.0%	57.51%	57.51%
Long-Term Debt Due	$860.0K
YoY Change
Total Short-Term Liabilities	$7.942M	$6.751M	$6.750M
YoY Change	28.13%	63.1%	63.08%
LONG-TERM LIABILITIES
Long-Term Debt	$30.00K	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$5.390K	$40.00K	$40.00K
YoY Change	-91.95%	-56.62%	-56.62%
Total Long-Term Liabilities	$35.39K	$40.00K	$40.00K
YoY Change	-47.13%	-56.62%	-56.62%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.942M	$6.751M	$6.750M
Total Long-Term Liabilities	$35.39K	$40.00K	$40.00K
Total Liabilities	$7.977M	$6.787M	$3.960M
YoY Change	27.33%	60.4%	176.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$25.17M	-$23.64M
YoY Change	11.04%	42.65%
Common Stock	$4.450K	$2.365M
YoY Change	18.07%	64937.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$7.848M	-$3.793M	-$3.790M
YoY Change
Total Liabilities & Shareholders Equity	$129.0K	$167.1K	$170.0K
YoY Change	-64.47%	-86.84%	-86.61%

Cashflow Statement

Concept	2023 Q4	2023 Q2	2023
OPERATING ACTIVITIES
Net Income	-$1.207M	-$590.0K	-$7.067M
YoY Change	-6.76%	-84.24%	-55.5%
Depreciation, Depletion And Amortization	$760.00	$0.00	$0.00
YoY Change	105.41%	-100.0%	-100.0%
Cash From Operating Activities	-$334.5K	-$130.0K	-$1.174M
YoY Change	-11.62%	-74.62%	-83.05%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$2.567K
YoY Change			-87.16%
Acquisitions
YoY Change
Other Investing Activities	$131.8K	-$10.00K	-$200.0K
YoY Change		-91.33%	73.37%
Cash From Investing Activities	$131.8K	-$10.00K	-$200.1K
YoY Change		-91.33%	47.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	220.0K	100.0K	$370.0K
YoY Change			-94.84%
NET CHANGE
Cash From Operating Activities	-334.5K	-130.0K	-$1.174M
Cash From Investing Activities	131.8K	-10.00K	-$200.1K
Cash From Financing Activities	220.0K	100.0K	$370.0K
Net Change In Cash	17.36K	-40.00K	-$1.004M
YoY Change	-104.59%	-93.63%	-1071.25%
FREE CASH FLOW
Cash From Operating Activities	-$334.5K	-$130.0K	-$1.174M
Capital Expenditures	$0.00	$0.00	$2.567K
Free Cash Flow	-$334.5K	-$130.0K	-$1.177M
YoY Change	-11.62%	-74.62%	-83.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6620100	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001481504
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2022Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.00001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	389433144	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	365239001	shares
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-54277
CY2023	dei	Entity Registrant Name EntityRegistrantName	XERIANT, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-1519178
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	Innovation Centre 1 3998 FAU Boulevard
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 309
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Boca Raton
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33431
CY2023	dei	City Area Code CityAreaCode	561
CY2023	dei	Local Phone Number LocalPhoneNumber	491-9595
CY2023	dei	Security12g Title Security12gTitle	Common Stock, $0.00001 par value
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Public Float EntityPublicFloat	30400000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2961705	usd
CY2022Q2	us-gaap	Minority Interest MinorityInterest	-2797611	usd
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	401033144	shares
CY2023	dei	Auditor Location AuditorLocation	Tampa, Florida
CY2023	dei	Auditor Firm AuditorFirmId	3289
CY2023Q2	us-gaap	Cash Cash	61625	usd
CY2022Q2	us-gaap	Cash Cash	1065945	usd
CY2023Q2	us-gaap	Prepaid Rent PrepaidRent	4529	usd
CY2022Q2	us-gaap	Prepaid Rent PrepaidRent	756	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	66154	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	1066701	usd
CY2023Q2	us-gaap	Deposits Assets Current DepositsAssetsCurrent	12546	usd
CY2022Q2	us-gaap	Deposits Assets Current DepositsAssetsCurrent	12546	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5507	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4409	usd
CY2023Q2	xeri	Operating Lease Right Of Use Asset1 OperatingLeaseRightOfUseAsset1	82911	usd
CY2022Q2	xeri	Operating Lease Right Of Use Asset1 OperatingLeaseRightOfUseAsset1	128342	usd
CY2023Q2	us-gaap	Investments Investments	0	usd
CY2022Q2	us-gaap	Investments Investments	57678	usd
CY2023Q2	us-gaap	Assets Assets	167118	usd
CY2022Q2	us-gaap	Assets Assets	1269676	usd
CY2023Q2	xeri	Accounts Payable And Accrued Liabilities AccountsPayableAndAccruedLiabilities	402568	usd
CY2022Q2	xeri	Accounts Payable And Accrued Liabilities AccountsPayableAndAccruedLiabilities	56836	usd
CY2023Q2	xeri	Accrued Liabilities Related Party AccruedLiabilitiesRelatedParty	20000	usd
CY2022Q2	xeri	Accrued Liabilities Related Party AccruedLiabilitiesRelatedParty	22000	usd
CY2023Q2	xeri	Shares To Be Issued SharesToBeIssued	75200	usd
CY2022Q2	xeri	Shares To Be Issued SharesToBeIssued	75200	usd
CY2023Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	5850000	usd
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3936185	usd
CY2023Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	100000	usd
CY2022Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	usd
CY2023Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	247254	usd
CY2022Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	0	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	55999	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	48963	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6751021	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4139184	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	36197	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	92197	usd
CY2023Q2	us-gaap	Liabilities Liabilities	6787218	usd
CY2022Q2	us-gaap	Liabilities Liabilities	4231381	usd
CY2023Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.00001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	389433144	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	365239001	shares
CY2023Q2	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	3894	usd
CY2022Q2	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	3652	usd
CY2023Q2	xeri	Common Stock To Be Issued CommonStockToBeIssued	51950	usd
CY2022Q2	xeri	Common Stock To Be Issued CommonStockToBeIssued	51950	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	19789793	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16351791	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23638461	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16571505	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-3792806	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-164094	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	-2827294	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	167118	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1269676	usd
CY2023	xeri	Consulting And Advisory Fees ConsultingAndAdvisoryFees	1101573	usd
CY2022	xeri	Consulting And Advisory Fees ConsultingAndAdvisoryFees	3031959	usd
CY2023	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	353000	usd
CY2022	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	432425	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	302693	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1184654	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	271021	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	444012	usd
CY2023	us-gaap	Marketing Expense MarketingExpense	23348	usd
CY2022	us-gaap	Marketing Expense MarketingExpense	651567	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5267581	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	2051635	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	11012198	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-2051635	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-11012198	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-461842	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-4629089	usd
CY2023	xeri	Financing Fees FinancingFees	0	usd
CY2022	xeri	Financing Fees FinancingFees	-43750	usd
CY2023	us-gaap	Interest Expense InterestExpense	10566	usd
CY2022	us-gaap	Interest Expense InterestExpense	138944	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-57368	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	usd
CY2023	xeri	Loss On Impairment Of Investment LossOnImpairmentOfInvestment	-156460	usd
CY2022	xeri	Loss On Impairment Of Investment LossOnImpairmentOfInvestment	0	usd
CY2023	us-gaap	Loss From Catastrophes LossFromCatastrophes	98781	usd
CY2022	us-gaap	Loss From Catastrophes LossFromCatastrophes	57678	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4259987	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-536	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5045004	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4869997	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-7096639	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-15882195	usd
CY2023	us-gaap	Income Loss Attributable To Noncontrolling Interest IncomeLossAttributableToNoncontrollingInterest	-29683	usd
CY2022	us-gaap	Income Loss Attributable To Noncontrolling Interest IncomeLossAttributableToNoncontrollingInterest	-2580925	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7066956	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13301270	usd
CY2023	xeri	Net Loss Per Common Share Basic And Diluted NetLossPerCommonShareBasicAndDiluted	-0.02
CY2022	xeri	Net Loss Per Common Share Basic And Diluted NetLossPerCommonShareBasicAndDiluted	-0.04
CY2023	xeri	Weighted Average Number Of Common Shares Outstanding Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted	375098691	shares
CY2022	xeri	Weighted Average Number Of Common Shares Outstanding Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted	345160167	shares
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	705306	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2078501	usd
CY2022	xeri	Shares Issued As Equity Kicker Amount SharesIssuedAsEquityKickerAmount	43750	usd
CY2022	xeri	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	128550	usd
CY2022	xeri	Conversion Of Series A Preferred To Common Stock Amount ConversionOfSeriesAPreferredToCommonStockAmount	0	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	426819	usd
CY2022	xeri	Inducement Of Conversion Interest Expense Amount InducementOfConversionInterestExpenseAmount	134929	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	761954	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3248181	usd
CY2022	xeri	Fair Value Of Beneficial Conversion Feature Associated With Convertible Debt FairValueOfBeneficialConversionFeatureAssociatedWithConvertibleDebt	2615419	usd
CY2022	xeri	Fair Value Of Warrants Associated With Convertible Debt FairValueOfWarrantsAssociatedWithConvertibleDebt	2777081	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-15882195	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2961705	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	48000	usd
CY2023	xeri	Conversion Of Series A Preferred To Common Stock Amount ConversionOfSeriesAPreferredToCommonStockAmount	0	usd
CY2023	xeri	Fair Value Of Warrants Associated With Convertible Debt FairValueOfWarrantsAssociatedWithConvertibleDebt	2688128	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	702116	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-7096639	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6620100	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-7096639	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-15882195	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1469	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	15581	usd
CY2023	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	702116	usd
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	3248181	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	48000	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	761954	usd
CY2023	xeri	Financing Fees1 FinancingFees1	0	usd
CY2022	xeri	Financing Fees1 FinancingFees1	43750	usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	134929	usd
CY2023	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	57368	usd
CY2022	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	usd
CY2023	xeri	Gains Losses On Extinguishment Of Debt1 GainsLossesOnExtinguishmentOfDebt1	4259987	usd
CY2022	xeri	Gains Losses On Extinguishment Of Debt1 GainsLossesOnExtinguishmentOfDebt1	0	usd
CY2023	xeri	Loss From Ebenberg Jv LossFromEbenbergJv	98781	usd
CY2022	xeri	Loss From Ebenberg Jv LossFromEbenbergJv	57678	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	156460	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	usd
CY2023	xeri	Amortization Of Debt Premium Discount AmortizationOfDebtPremiumDiscount	461842	usd
CY2022	xeri	Amortization Of Debt Premium Discount AmortizationOfDebtPremiumDiscount	4629089	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	45431	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	40867	usd
CY2023	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies	-3763	usd
CY2022	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies	480	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	145722	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7120	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3000	usd
CY2023	xeri	Increase Decrease Inshares To Be Issued IncreaseDecreaseInsharesToBeIssued	0	usd
CY2022	xeri	Increase Decrease Inshares To Be Issued IncreaseDecreaseInsharesToBeIssued	75200	usd
CY2023	xeri	Increase Decreaseinlease Liabilities IncreaseDecreaseinleaseLiabilities	-48964	usd
CY2022	xeri	Increase Decreaseinlease Liabilities IncreaseDecreaseinleaseLiabilities	-42643	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1174190	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6927249	usd
CY2023	xeri	Investment In Jv Movychem InvestmentInJvMovychem	-197563	usd
CY2022	xeri	Investment In Jv Movychem InvestmentInJvMovychem	-115356	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2567	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19990	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-200130	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-135346	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2078500	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	128550	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	4958950	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	370000	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	370000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7166000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1004320	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	103405	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1065945	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	962540	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61625	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1065945	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2023	xeri	Conversion Of Convertible Notes Payable And Accrued Interest ConversionOfConvertibleNotesPayableAndAccruedInterest	0	usd
CY2022	xeri	Conversion Of Convertible Notes Payable And Accrued Interest ConversionOfConvertibleNotesPayableAndAccruedInterest	426819	usd
CY2023	xeri	Warrants Issued With Convertible Notes Payable WarrantsIssuedWithConvertibleNotesPayable	2688128	usd
CY2022	xeri	Warrants Issued With Convertible Notes Payable WarrantsIssuedWithConvertibleNotesPayable	2777081	usd
CY2023	xeri	Beneficial Conversion Feature Arising From Convertible Notes Payable BeneficialConversionFeatureArisingFromConvertibleNotesPayable	0	usd
CY2022	xeri	Beneficial Conversion Feature Arising From Convertible Notes Payable BeneficialConversionFeatureArisingFromConvertibleNotesPayable	2615419	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23638461	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-7096639	usd
CY2023Q2	xeri	Working Capital WorkingCapital	-6684867	usd
CY2023	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.64	pure
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of beneficial conversion features and warrants associated with convertible debt. Actual results could differ from these estimates.</p>
CY2022	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	2615419	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	702116	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3248181	usd
CY2023	xeri	Warrants Issued WarrantsIssued	104802161	shares
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5267581	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	23348	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	651567	usd
CY2022	xeri	Warrants Issued WarrantsIssued	55512161	shares
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	21250000	shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	21250000	shares
CY2023	xeri	Stock Issued During Period Convertible Notes Payable StockIssuedDuringPeriodConvertibleNotesPayable	62283909	shares
CY2022	xeri	Stock Issued During Period Convertible Notes Payable StockIssuedDuringPeriodConvertibleNotesPayable	50968829	shares
CY2023	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	757395000	shares
CY2022	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	781132000	shares
CY2023	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	945731070	shares
CY2022	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	908862990	shares
CY2023	xeri	Movychem Non Performance Description MovychemNonPerformanceDescription	Xeriant ceased paying Movychem $25,000 per month as provided in the Joint Venture beginning December 2022
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	53327	usd
CY2022	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	54393	usd
CY2023Q2	xeri	Operating Lease Right Of Use Asset Before Accumulated Amortization OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization	220448	usd
CY2022Q2	xeri	Operating Lease Right Of Use Asset Before Accumulated Amortization OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization	220448	usd
CY2023Q2	xeri	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	-137537	usd
CY2022Q2	xeri	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	-92106	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	82911	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	128342	usd
CY2023Q2	xeri	Office Leas OfficeLeas	92196	usd
CY2022Q2	xeri	Office Leas OfficeLeas	141160	usd
CY2023Q2	xeri	Operating Lease Liability Current Portion OperatingLeaseLiabilityCurrentPortion	-55999	usd
CY2022Q2	xeri	Operating Lease Liability Current Portion OperatingLeaseLiabilityCurrentPortion	-48963	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	36197	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	92197	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	62201	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	37112	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	99313	usd
CY2023Q2	xeri	Present Value Discount PresentValueDiscount	-7117	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	92196	usd
CY2023Q2	us-gaap	Debt Instrument Convertible Carrying Amount Of The Equity Component DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent	5850000	usd
CY2022Q2	us-gaap	Debt Instrument Convertible Carrying Amount Of The Equity Component DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent	3936185	usd
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	5850000	usd
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	6050000	usd
CY2023Q2	xeri	Less Unamortized Discount LessUnamortizedDiscount	0	usd
CY2022Q2	xeri	Less Unamortized Discount LessUnamortizedDiscount	-2113815	usd
CY2023Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	5850000	usd
CY2022Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3936185	usd
CY2023Q2	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	50000	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2365419	usd
CY2023	xeri	Reacquisition Price Of Modified Convertible Debt Instrument ReacquisitionPriceOfModifiedConvertibleDebtInstrument	5950000	usd
CY2023	xeri	Reacquisition Price Of Fair Value Of Warrants ReacquisitionPriceOfFairValueOfWarrants	1918393	usd
CY2023	xeri	Reacquisition Price Of Cash Payment ReacquisitionPriceOfCashPayment	100000	usd
CY2023	xeri	Reacquisition Price Costs ReacquisitionPriceCosts	7968393	usd
CY2023Q2	xeri	Original Convertible Debt Instrument Carrying Value OriginalConvertibleDebtInstrumentCarryingValue	6050000	usd
CY2023Q2	xeri	Debt Discount Warrant Carrying Value DebtDiscountWarrantCarryingValue	-707585	usd
CY2023Q2	xeri	Original Issue Discount Carrying Value OriginalIssueDiscountCarryingValue	-341692	usd
CY2023Q2	xeri	Debt Discount Bcf Carrying Value DebtDiscountBcfCarryingValue	-602696	usd
CY2023Q2	xeri	Carrying Value Of Original Debt CarryingValueOfOriginalDebt	4398027	usd
CY2023	xeri	Convertible Debt Gains Losses On Extinguishment Of Debt ConvertibleDebtGainsLossesOnExtinguishmentOfDebt	3570366	usd
CY2023	xeri	Reacquisition Price Of Modified Convertible Debt Instrument1 ReacquisitionPriceOfModifiedConvertibleDebtInstrument1	5850000	usd
CY2023	xeri	Reacquisition Price Of Fair Value Of Warrants1 ReacquisitionPriceOfFairValueOfWarrants1	689621	usd
CY2023	xeri	Reacquisitionpriceofaccrued Short Term Liability ReacquisitionpriceofaccruedShortTermLiability	100000	usd
CY2023	xeri	Reacquisition Price Costs One ReacquisitionPriceCostsOne	6639621	usd
CY2023Q2	xeri	Carrying Value Of Original Debt1 CarryingValueOfOriginalDebt1	5950000	usd
CY2023	xeri	Loss On An Extinguishment LossOnAnExtinguishment	689621	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	461842	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4369735	usd
CY2023Q2	xeri	Carrying Value Of Auctus Note CarryingValueOfAuctusNote	5850000	usd
CY2022Q2	xeri	Carrying Value Of Auctus Note CarryingValueOfAuctusNote	3936185	usd
CY2023Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	270000	usd
CY2022Q3	xeri	Exercise Price ExercisePrice	0.09
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	10083	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	0	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21250000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y1M6D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21250000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2023Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.00001
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	389433144	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	365239001	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	4308600	shares
CY2022	xeri	Proceeds From Warrants Exercises ProceedsFromWarrantsExercises	128550	usd
CY2022	xeri	Common Stock Issued During Period Shares Issued For Services CommonStockIssuedDuringPeriodSharesIssuedForServices	4685615	shares
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	761954	usd
CY2022	xeri	Share Sold During Period ShareSoldDuringPeriod	39366666	shares
CY2022	xeri	Share Sold During Period Value ShareSoldDuringPeriodValue	2078501	usd
CY2022	xeri	Common Stock Issued For Prior Period Conversions Principal And Interest CommonStockIssuedForPriorPeriodConversionsPrincipalAndInterest	10598544	shares
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	167550	usd
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	4984	usd
CY2022	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	536	usd
CY2022	xeri	Common Stock Share Issued For Conversion CommonStockShareIssuedForConversion	4229680	shares
CY2022Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	250000	usd
CY2022	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	3749	usd
CY2022	xeri	Shares Issued For Common Stock In Exchange For The Inducement SharesIssuedForCommonStockInExchangeForTheInducement	845936	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	134929	usd
CY2023	xeri	Common Stock Issued During Period Shares Issued For Services CommonStockIssuedDuringPeriodSharesIssuedForServices	457143	shares
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	48000	usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	21250000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.12
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.12
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P1Y1M9D
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	0	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	20687500	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.12
CY2023	xeri	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms	P1Y1M9D
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	104802161	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	55512161	shares
CY2023	dei	Auditor Name AuditorName	Accell Audit & Compliance, PA

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001477932-23-007646-index-headers.html	Edgar Link	pending
0001477932-23-007646-index.html	Edgar Link	pending
0001477932-23-007646.txt	Edgar Link	pending
0001477932-23-007646-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
xeri-20230630.xsd	Edgar Link	pending
xeri_10k.htm	Edgar Link	pending
xeri_10kimg4.jpg	Edgar Link	pending
xeri_ex311.htm	Edgar Link	pending
xeri_ex312.htm	Edgar Link	pending
xeri_ex321.htm	Edgar Link	pending
xeri_ex322.htm	Edgar Link	pending
xeri-20230630_cal.xml	Edgar Link	unprocessable
xeri-20230630_pre.xml	Edgar Link	unprocessable
xeri-20230630_def.xml	Edgar Link	unprocessable
xeri-20230630_lab.xml	Edgar Link	unprocessable
xeri_10k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$XERI
XERIANT, INC. Stock $xeri

2023 Q4 Form 10-K Financial Statement

#000147793223007646 Filed on October 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XERI XERIANT, INC. Stock $xeri

2023 Q4 Form 10-K Financial Statement

#000147793223007646 Filed on October 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XERI
XERIANT, INC. Stock $xeri